Treatment After First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small- Cell Lung Cancer

Creative Commons License

KAZAZ S. N., ÖZTOP İ.

TURKISH THORACIC JOURNAL, cilt.18, sa.3, ss.66-71, 2017 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 18 Sayı: 3
  • Basım Tarihi: 2017
  • Doi Numarası: 10.5152/turkthoracj.2017.16042
  • Dergi Adı: TURKISH THORACIC JOURNAL
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.66-71
  • Anahtar Kelimeler: Epidermal growth factor receptor, tyrosine kinase inhibitors, resistance, non-small-cell lung cancer, ACQUIRED-RESISTANCE, GENE-MUTATIONS, EGFR MUTATION, NIVOLUMAB, AFATINIB, AMPLIFICATION, STRATEGIES, DOCETAXEL, ERLOTINIB, SAFETY
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Systemic treatment is the basic treatment approach to advanced-stage non-small-cell lung cancer (NSCLC), and chemotherapy and targeted treatments are commonly employed in these patients. Recently, positive results achieved with immunotherapy have led to a growing number of treatment options and prolonged survival time. Today, specific tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib, and afatinib, which target the epidermal growth factor receptor (EGFR), and the TKI crizotinib, which targets anaplastic lymphoma kinase gene rearrangement, have become the standard treatment among targeted therapies for patients with sensitive molecular anomalies. However, resistance develops against all these agents after a while. Numerous genetic mutations, T790M+ in particular, have been identified as resistance mechanisms against EGFR-TKIs, and researchers are developing specific inhibitors against them. Among those inhibitors, third-generation EGFR-TKIs such as osimertinib and rociletinib have gained prominence due to their high level of effectiveness and low toxicity profile. Besides, systemic chemotherapy and immunotherapy are proper alternatives. A second biopsy during the progression stage and better clarification of the mechanisms causing secondary resistance will enable more successful treatments in the future.